Chetan Pujara, Ph.D Chief Research & Development Officer, SpyGlass Pharma Dr. Pujara brings extensive industry experience to ...

Doerring, M.D., former FDA medical officer in the division of psychiatry and the founder and CEO of TaperClinic, he shares ...

- Jost Fischer, Chairman of AEON, will assume the role of interim CEO - ...

WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica” or the "Company”) (Nasdaq: VRCA ...

The agency OK’d an artificial vessel to restore blood flow in patients, even though its own scientists flagged questionable ...

The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, ...

WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) has announced the appointment of Dr. Noah L. Rosenberg as ...

About three months after leaving her post as the FDA’s principal deputy commissioner, Namandjé Bumpus, Ph.D., has found a new ...

Blujepa is the first new type of oral antibiotic to treat UTIs to gain approval in more than 20 years. Its development was ...

Achieves Significant Milestone with Expanded Use Indication, Opens Sizable New SI Market Opportunity ~ LOS GATOS, CA / ACCESS ...

Blujepa, which treats UTIs in female patients aged 12 and up with common and uncomplicated infections, will hit the market in ...

Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.